[Comment] A new pathway for primary aldosteronism treatment

An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that primary aldosteronism, when left untreated, is extremely dangerous. Strong evidence shows that patients with primary aldosteronism have a higher risk of heart disease, arrythmias, heart failure, stroke, and progressive renal injury compared with patients who have other forms of hypertension, even after adjustment for blood pressure.1 Primary aldosteronism is not just a risk factor, it is a distinct endocrinopathy, for which there are targeted therapeutic options: medical (mineralocorticoid receptor antagonists [MRAs]) and surgical (unilateral adrenalectomy).